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4D dose reconstructiona b s t r a c t
Purpose: Pencil beam scanned proton therapy (PBS-PT) treatment quality might be compromised by
interplay and motion effects. Via fraction-wise reconstruction of 4D dose distributions and dose accumu-
lation, we assess the clinical relevance of motion related target dose degradation in thoracic cancer
patients.
Methods and materials: For the ten thoracic patients (Hodgkin lymphoma and non-small cell lung cancer)
treated at our proton therapy facility, daily breathing pattern records, treatment delivery log-files and
weekly repeated 4DCTs were collected. Patients exhibited point-max target motion of up to 20 mm.
They received robustly optimized treatment plans, delivered with five-times rescanning in fractionated
regimen. Treatment delivery records were used to reconstruct 4D dose distributions and the accumulated
treatment course dose per patient. Fraction-wise target dose degradations were analyzed and the accu-
mulated treatment course dose, representing an estimation of the delivered dose, was compared with the
prescribed dose.
Results: No clinically relevant loss of target dose homogeneity was found in the fraction-wise recon-
structed 4D dose distributions. Overall, in 97% of all reconstructed fraction doses, D98 remained within
5% from the prescription dose. The V95 of accumulated treatment course doses was higher than 99.7% for
all ten patients.
Conclusions: 4D dose reconstruction and accumulation enables the clinical estimation of actual exhibited
interplay and motion effects. In the patients considered here, the loss of homogeneity caused by interplay
and organ motion did not show systematic pattern and smeared out throughout the course of fraction-
ated PBS-PT treatment. Dose degradation due to anatomical changes showed to be more severe and trig-
gered treatment adaptations for five patients.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 150 (2020) 268–274 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Pencil beam scanned proton therapy (PBS PT) treatments of
intrathoracic targets are associated with significant uncertainty.
Treatment quality may be compromised by setup errors, range
uncertainties, respiratory motion baseline shifts, anatomical
changes, delivery inaccuracies and motion of various sources (e.g.
respiration, cardiac motion, swallowing, etc.). More specifically,
the relative motion between a thoracic target volume and the scan-
ning proton beam can cause deviation of the delivered dose from
the planned dose and is referred to as the interplay effect. The
interplay effect has been of concern since the clinical introduction
of PBS PT [1] and has hampered its wide range clinical deployment
for the treatment of thoracic indications [2].
To generate PBS PT plans that are robust against possible uncer-
tainties, robust optimization techniques have been introduced andare increasingly used in clinical routine, especially when treating
moving targets. Outcomes of the robust optimization must be eval-
uated to check that robustness objectives are met. Robustness
evaluation is commonly performed through simulations of multi-
ple error scenarios [3]. The outcome of robustness evaluation
depends on the sampling of uncertainties. The more realistic and
comprehensive a robustness evaluation is, the more time consum-
ing and computationally expensive it gets, eventually making it
unfeasible for deployment in clinical routine on regular basis.
Especially the assessment of the clinical impact of the interplay
effect is difficult due to the large parameter space affecting it and
has been subject of many in-silico simulation studies [4–8]. Three
sets of parameters determine the interplay effect: (i) delivery char-
acteristics in the sense of the delivery timeline, the start of delivery
with respect to the organ motion (starting phase), the scanning
path, the spot size, the number of applied rescans, the type of res-
canning (e.g. layered or volumetric rescanning) and the use of, e.g.,
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number of fields and layer spacing and (iii) patient characteristics
such as the patient and fraction specific motion pattern in terms of
amplitude, frequency and variability and the target volume size
and location. Due to this large amount of variables, the impact of
the interplay effect for a specific patient so far has only been
assessed in a probabilistic manner by simulating several possible
delivery scenarios with varying input parameters (e.g. the starting
phase, the number of rescans, etc.). In this way, possible deviations
of the delivered dose from the planned dose can be estimated.
However, it remains unknown what is the probability of one sce-
nario over another and there is lack of insight on what dose actu-
ally is delivered to the patient. Consequently, when correlating
outputs to the planned treatment dose, this correlation is impeded
by the unknown deviation of the actual delivered dose from the
planned dose.
Accounting for dose delivery uncertainties by robust optimiza-
tion, considering many of possible treatment scenarios, comes at
the cost of integral dose and dose to healthy tissues. However,
for every individual patient only one scenario occurs. By creating
overly robust plans, the normal tissue may be unnecessarily over-
dosed to compensate for situations that may never happen in
practice.
Contrasting the concept of ‘‘overly conservative” robust opti-
mization is the concept of adaptive treatment delivery [9]. Here,
much more conformal treatment plans can be delivered on the
basis that deviations from the nominal scenario are accounted
for by a plan adaptation. Adaptation can either be triggered based
on continuous accumulation and evaluation of the delivered dose
distribution or executed on a daily basis or even real-time in the
future. However, that requires high degree and reliability of
automation. A triggered adaptation relies on an assessment of
the actual delivered fraction dose, which in general is challenging
to obtain, especially for thoracic indications due to motion affect-
ing the treatment delivery.
We have developed a methodology aimed at gaining more
insight on fraction-wise delivered dose distributions. This method-
ology is based on retrospective reconstruction of four-dimensional
(4D) dose distributions and accumulation providing means to con-
tinuously assess treatment course quality [10]. 4D dose reconstruc-
tion for carbon ion has previously been reported on by Richter et al.
[11]. In the current study commercially available solutions have
been used to implement the dose reconstruction workflow, differ-
ent indications and much longer fractionation schemes with mul-
tiple repeat CTs have been investigated. Furthermore,
investigated treatment plans have been prepared using robust
optimization and evaluation planning techniques.
Here we present initial results of the application of 4D dose
reconstruction and accumulation (4DREAL) of 10 consecutive
patients with thoracic indications (Hodgkin lymphoma (post-
chemotherapy) and non-small cell lung cancer (NSCLC)) treated
with PBS PT at our facility. The focus of this study is to primarily
evaluate fraction-wise and consecutive accumulated target volume
doses (high dose area). The objective is to assess the impact of the
interplay and organ motion on the target dose homogeneity and to
investigate the consequences of fraction-wise loss of homogeneity
on the total accumulated course dose.Material and methods
In our facility the treatment of targets, which are affected by
respiratory motion, is performed following a procedure based on
four principles: (1) motion assessment, (2) robust planning, (3)
robustness evaluation and (4) retrospective 4D dose
reconstruction.(1) Motion assessment
Planning 4DCT (phase-based reconstruction) is used to assess
the magnitude of the motion. Phase-based reconstructions are
more suitable for dose calculations due to equidistant spacing in
time, however, may suffer from anatomy-induced artifacts, which
could be less pronounced in amplitude-based reconstructions [12].
End-of-inhale and -exhale phases are defined by a medical doctor
(MD) in consultation with a medical physicist (MP). Afterwards,
the MD defines the target volumes on the selected phases, which
are later used for the definition of the CTV and ITV as per ICRU62.
ITV was obtained as a union of the CTVs of the end-of-inhale and
exhale phases. Deformable image registration (DIR) is performed
between the selected phases using Anatomy Constrained Deforma-
tion Algorithm (ANACONDA). Deformation vector fields are evalu-
ated by a MP to quantify the extent of motion within target
volume. Motion is assessed in terms of average motion of the tar-
get volume and maximum motion of any voxel (point-max).
Depending on the extent of the motion the approach to treatment
planning and delivery is fine-tuned. For example, decisions are
made regarding the field selection and design, enlargement of
the spot size [13] exact rescanning strategy [4,6] etc.
(2) Robust planning
Currently all patients in our clinic receive 3D robust optimized
treatments plans. Specifically, for NSCLC patients this decision was
based on a preclinical study, in which 3D and 4D robust optimiza-
tion techniques were compared in terms of achievable plan robust-
ness [14]. This pre-clinical study was conducted utilizing 4D
robustness evaluation method (4DREM) introduced by Ribeiro
et al. [3]. 3D robust optimization is performed on a single image
set (average CT of the planning 4DCT) and accounts for setup and
range uncertainty. Optimization for lung cancer patients is per-
formed assuming 6 mm setup uncertainty, while optimization for
Hodgkin lymphoma is performed assuming 5 mm setup uncer-
tainty. This is due to immobilization differences and setup repro-
ducibility. Hodgkin lymphoma patients are typically immobilized
with a 5-point thermoplastic mask as opposed to NSCLC patients,
who are immobilized on a wing board. Estimated range uncer-
tainty for all above mentioned indications is 3%, based on the
experimental evaluation as shown by Meijers et al. [15] where
the evaluation of range accuracy has been performed for average
CT-based calculations, as well as for phase-based calculations.
For our patient cohort, all plans incorporated 5-times rescanning
(in-layer scaled rescanning). For all lymphoma patients spot size
was intentionally enlarged by retracting the range shifter, while
for NSCLC patients no intentional spot size enlargement was done.
The decision regarding the enlargement of spot size for NSCLC was
also based on the pre-clinical study mentioned above, which
showed that robust plans can be achieved without enlargement
of the spot size, however, during the plan optimization ITV, defined
on the average CT, for NSCLC cases was overridden with a muscle
tissue density. All lymphoma patients were treated with
anterior, anterior-oblique beam arrangement (minimum of 2
fields) and all NSCLC cases were planned with 3-field arrangement.
For NSCLC patients anterior, lateral and/or posterior beam direc-
tions were used depending on the exact location of the target
volume.
Proton spot size in our facility is 3–6.5 mm (sigma) as a function
of proton energy, which varies from 230 to 70 MeV respectively.
Spot spacing as a function of the spot full width at the half maxi-
mum (FWHM) in water with a ratio of 0.8–1 was used during plan
optimization. Energy layers were spaced as a function of peak
width with a ratio of 0.8–1. Peak width in our facility is 8.7–
1.7 mm as a function of energy (230–70 MeV respectively). Layer
270 Log-based 4D dose reconstruction and accumulationswitching time is approximately 0.7–0.9 s depending on the energy
step.
(3) Robustness evaluation
Robustness evaluation was performed to assess the outcome of
robust optimization. Robustness evaluation was performed in 3D,
simulating a set of scenarios with pre-defined setup and range
errors. 28 scenarios are calculated, simulating range errors of +/
3% in combination with setup errors of +/ 6 or +/ 5 mm, depend-
ing on the indication as mentioned above. Robustness of the plan
was assessed on the basis of voxel-wise minimum and voxel-
wise maximum dose distributions. In our facility plans are consid-
ered robust if V95 of the target volume on voxel-wise minimum
distribution exceeds 98% [16].
(4) Retrospective 4D dose reconstruction
4D dose reconstruction is performed following the method
described by Meijers et al. [10]. This method makes use of treat-
ment delivery log files, patient’s breathing signals and most recent
available 4DCT information throughout the treatment course.
Fraction-wise breathing patterns of each patient are acquired
using the Anzai belt system (Anzai Medical, Tokyo, Japan). After
the delivery of each fraction, treatment delivery log files are col-
lected. Among other data, log files contain information for every
delivered spot regarding its position, dose in terms of monitor
units (MU), energy and timing. Based on the timing informationFig. 1. Schematic representation of the 4D dose reconstof the breathing signal, delivered spots, as retrieved from the log
files, are sorted into corresponding breathing phases. Afterwards,
the spots are written into a set of DICOM sub-plans, where each
sub-plan contains only the spots associated with a specific breath-
ing phase. These sub-plans are imported into the treatment plan-
ning system (TPS), and each sub-plan is calculated on the
corresponding phase of the 4DCT. In this step, the most recent
available 4DCT is used. In our current clinical practice, patients that
are subject to respiratory motion receive weekly repeated 4DCTs.
An exception are Hodgkin lymphoma patients, for whom 4DCT in
the last week of the treatment may be skipped, if no observations
with clinical consequences were made based on daily CBCTs and
previous 4DCTs.
Deformation vector fields between a fraction-wise reference
phase and all other phases of the 4DCT data set are defined. In
the majority of cases, the reference phase is the end-of-exhale
phase. Deformation vector fields are used to warp dose contribu-
tions of all sub-plans per fraction to the fraction-wise reference
phase, where they are summed. Afterwards, deformation vector
fields between a course-wise reference phase and fraction-wise
reference phase are defined and the fraction-wise summed dose
is warped to the course-wise reference phase. On the course-
wise reference phase, individual fraction doses are accumulated.
The same course-wise reference phase (and target volume) is used
throughout the treatment course (also in case plan adaptations
have been made). Course-wise reference phase, for example, could
be the end-of-exhale phase of the planning CT. Schematically the
workflow is shown in Fig. 1.ruction and accumulation workflow for n fractions.
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calculated for the 10 consecutive patients affected by motion and
treated at our proton facility. Table 1 summarizes some of the
planning and target characteristics of these cases.
ITV V95vox-min is V95 based on the voxel-wise minimum dose
distribution, derived in the process of robustness evaluation. This
parameter is a measure of the robustness for the initial treatment
plan.Results
Due to the difference in indications, various fractionation
schemes and patient-related events, the available data per patient
and some treatment characteristics varied among patients. The
number of acquired repeat CTs, the number of treatment plan
adaptations, the number of fractions, for which breathing signal
was acquired and the smallest and the largest observed point-
max motions between the end-of-inhale and -exhale phases and
mean motions as observed on repeat CTs are listed in Table 2.
For some of the fractions, the acquisition of the breathing signal
was skipped either due to logistical issues or patient-related issues.
For patient 2 one of the fractions was delivered on a linac due to
pending evaluation of the repeat CT, where large anatomical vari-
ations were observed. For patient 5 the last two fractions were
delivered on a linac in a satellite site due to hospitalization of
the patient unrelated to the radiotherapy treatment itself.
All plan adaptations were necessary due to anatomical changes.
Changes in the volume of postoperative fluid caused adaptations
for patients 2 and 3. For patient 6 adaptation was triggered by a
tumor shrinkage, which resulted in an unacceptable dose to OARs.
Weight gain required a plan adaption for patient 7. While disap-
pearance of pleural effusion caused plan adaptation for patient 9.
For all follow up 4DCTs the motion evaluation was performed
according to the previously described methodology. For example,
for patient 6, due to tumor shrinkage, during the course maximumTable 1
Characteristics of the treatment course preparation specifics for the 10 patients. The point-
volume based on the planning 4DCT.
Pat. # Indication Prescription ITV volume, cm3
01 Lymphoma 15  2.0 GyRBE 166
02 NSCLC 25  2.4 GyRBE 44
03 NSCLC 25  2.4 GyRBE 243
04 NSCLC 25  2.4 GyRBE 131
05 NSCLC 25  2.4 GyRBE 357
06 NSCLC 25  2.4 GyRBE 217
07 NSCLC 25  2.4 GyRBE 298
08 NSCLC 25  2.4 GyRBE 202
09 NSCLC 25  2.4 GyRBE 336
10 Lymphoma 15  2.0 GyRBE 339
Table 2
Available data and treatment characteristics for the 10 considered patients. Mean and poin
values, as observed on any one specific repeat CT.
Pat. # Repeat CTs Plan adaptations Breathing signals, [available/tota
01 2 0 15/15
02 5 2 24/25
03 5 1 23/25
04 5 0 22/25
05 5 0 22/25
06 5 1 25/25
07 5 1 25/25
08 5 0 25/25
09 5 1 25/25
10 3 0 15/15amplitude of the motion increased significantly, reaching 11 mm
as opposed to 5 mm observed in the initial planning CT.
Table 3 shows the summary of observations made on the basis
of fraction-wise and accumulated treatment course dose distribu-
tions. Mean D98 and D2 (with SD) for the CTV are listed per patient
for all reconstructed fractions of the treatment course. In addition,
D98, D2 and V95 of the accumulated treatment course dose distri-
bution are shown.
As an example, Fig. 2 shows all reconstructed 4D fractions and
accumulated course dose for patients 1 and 2. Additionally
supplementary material 1 shows all reconstructed and accumu-
lated doses for all patients.
Out of total 221 reconstructed fractions combined for all 10
patients presented in this study dose to the target volume (D98)
remained within 5% from the prescription dose, with only 6 frac-
tions being an exception. In no case, accumulated treatment course
dose distributions showed major variations from the prescription
dose.
Organ at risk (OAR) doses are summarized in supplementary
material 2 for illustrative purposes. However, due to the limita-
tions of accumulated doses, as discussed further, and the set scope
of the work, OAR doses will not be discussed in detail.Discussion
It can be observed that interplay effects and organ motion intro-
duce loss of dose homogeneity in the target volume on fraction
basis. Furthermore, this scales with the degree of target motion.
One may notice that the loss of homogeneity for Hodgkin lym-
phoma is smaller than the loss of homogeneity for NSCLC. For
the included NSCLC patients, whole target volumes in the lung
were mobile, while for lymphoma patients large parts of the treat-
ment volume are relatively immobile, as parts are located cranially
with respect to the lung. Therefore, the organ motion on average is
affecting this area to a lesser extent.max motion corresponds to the maximum motion observed for any voxel in the target











t-max motions are shown as the range between the smallest and the largest motion












CTV dose statistics based on reconstructed fraction doses and accumulated course dose. Mean D98 and D2 doses and V95 are mean over all the fractions. In the brackets the
lowest and the highest values, as observed for any one of the fractions, are provided. A single course-wise CTV, as defined on the reference image set, has been used for the DVH
analysis per patient.
Pat. # Prescription, GyRBE Mean D98 (min–max), GyRBE Mean D2 (min–max), GyRBE Mean V95 (min–max), % Acc. D98, GyRBE Acc. D2, GyRBE Acc. V95, %
01 30 29.7 (29.5–29.8) 31.1 (30.8–31.5) 100 (100–100) 29.9 30.9 100.0
02 60 59.1 (58.3–59.9) 62.2 (61.4–63.3) 100 (100–100) 60.0 61.4 100.0
03 60 57.9 (56.4–58.8) 61.9 (61.4–62.8) 99.1 (96.5–100) 58.4 61.1 99.8
04 60 59.5 (58.9–59.8) 61.6 (61.2–61.9) 100 (100–100) 59.8 61.4 100.0
05 60 59.4 (59.0–59.8) 62.3 (61.6–63.4) 100 (99.9–100) 59.7 62.0 100.0
06 60 58.9 (57.3–59.9) 62.1 (61.3–62.6) 99.9 (99.1–100) 59.8 61.4 100.0
07 60 58.8 (56.4–59.8) 62.3 (61.2–63.1) 99.4 (97.5–100) 59.5 61.9 99.7
08 60 59.2 (58.4–59.7) 61.9 (61.5–62.4) 100 (100–100) 59.7 61.4 100.0
09 60 58.9 (58.0–59.6) 62.0 (61.5–62.6) 99.9 (99.6–100) 59.4 61.6 100.0
10 30 29.6 (29.4–29.7) 30.6 (30.4–31.2) 100 (100–100) 29.7 30.4 100.0
Fig. 2. DVHs of CTV for reconstructed fraction-wise 4D dose distributions and accumulated course dose. DVHs are corresponding to cases 1 and 2. Fraction doses are shown in
color, while accumulated course dose is shown in black. Fraction doses that have been calculated on the same 4DCT also share the same color. Assigned colors are red, yellow,
green, light blue and blue, corresponding from an earlier 4DCT to a more recent in this order.
272 Log-based 4D dose reconstruction and accumulationIn the current data set it was not observed that loss of homo-
geneity induced by motion effects follow a systematic pattern. Sys-
tematic patterns generally were caused by anatomical variations,
such as, changes in postoperative fluids, patient’s weight changes
or tumor shrinkage. In all cases, although loss of homogeneity
was present on fractional basis, homogeneity was recovered when
performing dose accumulation. Local hot and cold spots did not
occur in the same location in different fractions.
Although fractionation likely smears out interplay and organ
motion effects over the course of radiotherapy, these effects should
be considereddifferentlywhenmoving towardshypo-fractionation.
In such case, loss of homogeneity very likelymayhave clinical impli-
cations. Nevertheless, it should be noted that for the initial 10
patient data set the observed average target volume motion is rela-
tively low. That is due to the introduced guideline to initially limit
the point-max motion below 10 mm during the patient selection
(although this was not strictly followed anymore for the patient
10). This illustrates how the 4DREAL methodology can be applied
in clinical practice to gradually expand patient inclusion criteria,
while ensuring close daily monitoring of the treatment course.Limitations
We would like to point out several important assumptions that
are made, when performing 4D dose reconstruction and accumula-
tion as described in this study.
(1) Planning and repeat 4DCTs are assumed to be good repre-
sentations of patient’s anatomy. By reviewing daily CBCTs
and comparing them to repeat CTs, one can judge whether
the repeat CT is representing the daily anatomy, however
this is a subjective evaluation. In case of non-minor inconsis-
tencies, it is difficult to estimate the actual impact of these
observations on the calculated dose distributions. In the
future, this limitation might be overcome by introducing
post-processed synthetic 4DCTs based on daily CBCTs suit-
able for proton dose calculations. There are multiple exam-
ples for developments towards introduction of 4DCBCTs
[17] and synthetic CTs [18] which do have improved CT
number accuracy that might make synthetic 4DCTs suitable
for proton dose calculation. The initial investigations on the
A. Meijers et al. / Radiotherapy and Oncology 150 (2020) 268–274 273use of artificial intelligence for reduction of motion-induced
artifacts in the 4DCT also show promising results [19]. This
may further improve 4DCT quality.
(2) It is assumed that 4DCT, which captures the average patient
motion derived from multiple breathing cycles, is represen-
tative of the patient’s 4D anatomy. Patients exhibiting irreg-
ular breathing may be identified calculating the ratio of
extreme inhalation amplitude and regular tidal inhalation
amplitude [20]. However, breathing cycles are not constant
over time. Therefore, potentially a better accuracy of dose
reconstruction could be achieved by introducing, so called,
‘‘5DCTs”. 5DCT can be obtained by combining 4DCTs of vari-
able motion characteristics, each representing an individual
breathing cycle. Developments [21] are ongoing, which aim
at modeling variations of subsequent breathing cycles. These
models can be used to animate 4DCT and generate 5DCTs,
incorporating breathing cycle variability. However, valida-
tion and, therefore, quantification of accuracy, remains a
major challenge for these approaches and eventually these
images would provide only an estimation about the motion.
Consequently, the added value of 5DCT in dose reconstruc-
tion and the impact of its uncertainty remains a topic for fur-
ther investigations.
(3) Our dose reconstruction method heavily depends on dose
warping. The accuracy and physical meaning of the warped
doses is a topic for further investigations. For example, the
effect of voxel volume deformation on the meaning of dose
must be further clarified. Also, the radiobiological effect on
addition of fractionated and varying doses per voxel should
be further investigated. For variations of up to +/- 10% in
high dose area the additional radiobiological effect has been
estimated to be minimal [22]. However, variations per voxel
in low dose areas might be much larger and their radiobio-
logical consequences for dose addition is a subject for fur-
ther clarifications. Due to this, within the scope of current
evaluation, we did not investigate low dose areas or dose
to OARs, but primarily focused on high dose areas and uni-
formity of the dose within target volume. To some extent
geometric accuracy of the dose warping in the phantom
study was investigated during the development of the
methodology [10] by being able to reconstruct with a sub-
millimeter accuracy the shadow caused by a moving ball
bearing in the beam path. However, it has been shown that
the accuracy of dose warping reduces when the magnitude
of the deformation increases [23]. Also, further investigation
on dosimetric consequences caused by the use of different
DIR algorithm are required [24].
Currently the smoothness of deformation vector fields is
assessed by visual inspection of the deformation grids and accu-
racy is assessed by manual review of the mapped contours. In case
of major anatomical changes, which cannot be attributed to the
deformations, deformable image registration would fail. For none
of the cases presented here this was the case. However, such sce-
nario is highly probable in clinical routine, in which case corrective
actions would be necessary. Otherwise, the meaning of warped
doses would become even more questionable. To some extent such
situations might be corrected by manual adjustment of control
contours and use of them as control ROIs during DIR.
(4) Currently our implementation of 4D dose reconstruction
method does not allow to account for residual patient setup
errors or residual beam delivery discrepancies. However, we
use 4D dose reconstruction primarily as a tool for gaining
insights into interplay and organ motion effects.In addition to 4D dose reconstruction we perform robustness
evaluation on repeat CTs to assess robustness against residual
setup errors and range uncertainties. Combined effects of interplay
effect, organ motion, setup errors, range uncertainty and changing
anatomy indeed might cause some additional dose perturbations.
However, since we do not observe systematic patterns linked to
interplay from fraction to fraction, it is likely that these additional
perturbations would not have severe effects on treatment course
dose due to fractionation.
Due to these assumptions and in an absence of further evalua-
tions, we do not recommend considering reconstructed and accu-
mulated dose distributions as ‘‘clinical” doses. Therefore, at this
stage we would not use accumulated dose distributions, for exam-
ple, as a background (in otherwords, ‘‘already delivered”) dose to be
used in plan optimization in case of plan adaptations. However, it
would be an attractive use case for the accumulated doses if some
of the limitations would be addressed or proven not relevant. This
way accumulated hot or cold spots or unintended dose to OARs
could be directly mitigated during the plan adaptation process.
The proposed 4D dose calculation workflow can also be
employed prospectively by using simulated breathing patterns
and log files from the dry-runs. In such way for cases, when motion
amplitude exceeds predefined acceptable levels, a set of simulated
fractions can be generated to assess if fraction-wise hot/cold spots
have systematic behavior. If this is not the case, accumulated DVH
would converge towards steeper curve.
Furthermore, a promising future application of accumulated
dose distributions could be its correlation with treatment out-
comes. This could clarify the clinical relevance of fraction dose
variations and could help to reduce uncertainties in the dose
parameters enclosed in TCP and NTCP models.
Eventually, the use of daily treatment related information (de-
livery log files, imaging data, breathing signals, etc.,) could be auto-
matically retrieved and processed in a dose accumulation
workflow. By introducing warning and action levels for accumu-
lated doses or even using accumulated dose to track TCP and / or
NTCP values, it would be possible to implement a whole new layer
of quality control longitudinally throughout the treatment course.
By using adaptive loops in this process, it would be possible to
ensure and gain more confidence that initial clinical goals are
met at the end of the treatment course.
In conclusion, the developed methodology for fraction-wise 4D
dose reconstruction was applied to 10 consecutive thoracic
patients, subject to respiratory motion. Contrary to findings in
prospective simulation studies, we did not observe any clinically
relevant loss of target dose homogeneity due to interplay and
motion effects. Fraction-wise loss of target dose homogeneity
due to interplay and organ motion showed no systematic pattern
and smeared out with fractionation. Dose degradation caused by
anatomical changes showed to be more severe and caused treat-
ment adaptations in five out of ten patients. Although, warped dose
distributions should be interpreted with caution, this study pro-
vides more realistic incremental insight into the effect of breathing
related organ motion on PBS-PT dose delivery.Funding
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